News on therapeutic management of MDR-tuberculosis: a literature review

References

• Global tuberculosis report 2016. [cited 2017 Mar 8] Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1
   Google Scholar
• M’imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev. 2012;5:CD006591.
   Google Scholar
• Hoagland DT, Liu J, Lee RB, Lee RE. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Delivery Rev. 2016;102:55–72.10.1016/j.addr.2016.04.026
   PubMed Web of Science ®Google Scholar
• Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(3):S201–7.
   PubMed Web of Science ®Google Scholar
• Brigden G, Nyang’wa B-T, du Cros P, Varaine F, Hughes J, Rich M, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68–74.10.2471/BLT.13.122028
   PubMed Web of Science ®Google Scholar
• WHO treatment guidelines for drug-resistant tuberculosis; 2016 update. October 2016 revision, WHO/HTM/TB/2016.04 in the place of reference 6. Available from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf?ua=1
   Google Scholar
• Mdluli K, Ma Z. Mycobacterium tuberculosis DNA Gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007;7(2):159–68.10.2174/187152607781001763
   PubMedGoogle Scholar
• Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev. 2013;6:CD004795.
   PubMedGoogle Scholar
• Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2015;32:118–23.
   PubMed Web of Science ®Google Scholar
• Aung KJM, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18(10):1180–7.
   PubMed Web of Science ®Google Scholar
• Chiang C-Y, Van Deun A, Rieder HL. Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016;20(9):1143–7.
   PubMed Web of Science ®Google Scholar
• Koh W-J, Lee SH, Kang YA, Lee C-H, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858–864.10.1164/rccm.201303-0604OC
   PubMed Web of Science ®Google Scholar
• Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. The Lancet. 2015;385(9979):1738–47.10.1016/S0140-6736(14)62002-X
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, et al. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011;55(4):1781–3.10.1128/AAC.01514-10
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Sundaramurthi JC, Palaniappan AN, Narayanan S. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis. Tuberculosis. 2016;101:31–40.10.1016/j.tube.2016.08.002
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432–442.10.1016/S1473-3099(03)00671-6
   PubMed Web of Science ®Google Scholar
• Wilson JW, Tsukayama DT. Extensively drug-resistant tuberculosis: principles of resistance, diagnosis, and management. Mayo Clin Proc. 2016;91(4):482–495.10.1016/j.mayocp.2016.01.014
   PubMed Web of Science ®Google Scholar
• Wilson JW, Tsukayama DT. The molecular genetics of fluoroquinolone resistance in mycobacterium tuberculosis. Microbiol Spectr. 2014;2(4):MGM2-0009-2013.
   PubMedGoogle Scholar
• Shirude PS, Hameed S. Chapter twenty-one – nonfluoroquinolone-based inhibitors of mycobacterial type II topoisomerase as potential therapeutic agents for TB. In: Desai MC, editor. Annual reports in medicinal chemistry. Vol. 47, Burlington: Academic Press; 2012. p. 319–30.
   Google Scholar
• Chopra S, Matsuyama K, Tran T, Malerich JP, Wan B, Franzblau SG, et al. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother. 2012;67(2):415–421.10.1093/jac/dkr449
   PubMed Web of Science ®Google Scholar
• Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015;59(3):1455–65.10.1128/AAC.04347-14
   PubMed Web of Science ®Google Scholar
• Shirude PS, Madhavapeddi P, Tucker JA, Murugan K, Patil V, Basavarajappa H, et al. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating mycobacterium tuberculosis. ACS Chem Biol. 2013;8(3):519–23.10.1021/cb300510w
   PubMed Web of Science ®Google Scholar
• Schroeder EK, de Souza O., Santos DS, Blanchard JS, Basso LA. Drugs that inhibit mycolic acid biosynthesis in mycobacterium tuberculosis. Curr Pharm Biotechnol. 2002;3(3):197–225.10.2174/1389201023378328
   PubMedGoogle Scholar
• Brossier F. Mécanismes d’action et de résistance de l’isoniazide, un antituberculeux de première ligne. J Anti-Infect. 2011;13(4):217–227.10.1016/j.antinf.2011.10.003
   Web of Science ®Google Scholar
• Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2008;12(2):139–45.
   PubMed Web of Science ®Google Scholar
• Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–9.10.1016/S1473-3099(10)70139-0
   PubMed Web of Science ®Google Scholar
• Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med. 2008;2(4):455–71.10.1586/17476348.2.4.455
   PubMedGoogle Scholar
• Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–9.10.1128/AAC.00753-13
   PubMed Web of Science ®Google Scholar
• Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014;5(3):222–4.10.4103/0976-500X.136121
   PubMedGoogle Scholar
• Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol. 2013;21(9):493–501.10.1016/j.tim.2013.05.002
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.10.1371/journal.pmed.0030466
   PubMed Web of Science ®Google Scholar
• Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. New Engl J Med. 2012;366(23):2151–2160.10.1056/NEJMoa1112433
   PubMed Web of Science ®Google Scholar
• Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91–100.10.1007/s40265-014-0331-4
   PubMed Web of Science ®Google Scholar
• Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–400.10.1183/09031936.00125812
   PubMed Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. New Engl J Med. 2015;373(20):1986–8.10.1056/NEJMc1505196
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54(8):3402–7.10.1128/AAC.01354-09
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012;56(6):3027–31.10.1128/AAC.06125-11
   PubMed Web of Science ®Google Scholar
• Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015;59(1):129–35.10.1128/AAC.03822-14
   PubMed Web of Science ®Google Scholar
• New TB Drugs – TBA 354. 2016. [cited 2017 Mar 8] Available from: http://www.newtbdrugs.org/pipeline/compound/tba-354
   Google Scholar
• Sacksteder KA, Protopopova M, Barry CE, Andries K, Nacy CA. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 2012;7(7):823–37.10.2217/fmb.12.56
   PubMed Web of Science ®Google Scholar
• Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother. 2007;51(4):1563–5.10.1128/AAC.01326-06
   PubMed Web of Science ®Google Scholar
• Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother. 2015;70(5):1558–66.10.1093/jac/dku553
   PubMed Web of Science ®Google Scholar
• Bogatcheva E, Hanrahan C, Nikonenko B, et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg Med Chem Lett. 2011;21(18):5353–7.10.1016/j.bmcl.2011.07.015
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang Y, Lu J, Pang Y. In vitro activity of β-lactams in combination with β-lactamase inhibitors against multidrug-resistant mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2015;60(1):393–9.
   PubMed Web of Science ®Google Scholar
• Dhar N, Dubée V, Ballell L, Cuinet G, Hugonnet J-E, Signorino-Gelo F, et al. Rapid cytolysis of mycobacterium tuberculosis by faropenem, an orally bioavailable β-Lactam antibiotic. Antimicrob Agents Chemother. 2014;59(2):1308–19.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, D’Ambrosio L, Centis R, Tiberi S, Esposito S, Dore S, et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci. 2016;17(3):373.10.3390/ijms17030373
   PubMed Web of Science ®Google Scholar
• Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, et al. Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009;324(5928):801–4.10.1126/science.1171583
   PubMed Web of Science ®Google Scholar
• Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(11):5790–5793.10.1128/AAC.01476-12
   PubMed Web of Science ®Google Scholar
• New TB drugs – PBTZ 169 [cited 2017 Mar 8] Available from: http://www.newtbdrugs.org/pipeline/compound/pbtz-169
   Google Scholar
• Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med. 2014;6(3):372–83.10.1002/emmm.201303575
   PubMed Web of Science ®Google Scholar
• Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, et al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Nat Acad Sci USA. 2013;110(27):E2510–7.10.1073/pnas.1309171110
   PubMed Web of Science ®Google Scholar
• Ishizaki Y, Hayashi C, Inoue K, Igarashi M, Takahashi Y, Pujari V, et al. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem. 2013;288(42):30309–19.10.1074/jbc.M113.492173
   PubMed Web of Science ®Google Scholar
• Chetty S, Ramesh M, Singh-Pillay A, Soliman MES. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett. 2017;27(3):370–86.10.1016/j.bmcl.2016.11.084
   PubMed Web of Science ®Google Scholar
• Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg. 2016;110(3):163–72.10.1093/trstmh/trv107
   PubMed Web of Science ®Google Scholar
• Alcalá L, Ruiz-Serrano MJ, Turégano CP-F, de Viedma DG, Díaz-Infantes M, Marín-Arriaza M, et al. In vitro activities of linezolid against clinical isolates of mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003;47(1):416–417.10.1128/AAC.47.1.416-417.2003
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, Alffenaar J-WC, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–42.10.1183/09031936.00022912
   PubMed Web of Science ®Google Scholar
• Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J. 2012;39(4):956–62.10.1183/09031936.00076811
   PubMed Web of Science ®Google Scholar
• Zhang L, Pang Y, Yu X, Wang Y, Gao M, Huang H, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection. 2014;42(4):705–11.10.1007/s15010-014-0632-2
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–18.10.1056/NEJMoa1201964
   PubMed Web of Science ®Google Scholar
• Koh W-J, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67(6):1503–7.10.1093/jac/dks078
   PubMed Web of Science ®Google Scholar
• De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D’Ambrosio L, Tiberi S, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013;41(6):1386–92.10.1183/09031936.00124312
   PubMed Web of Science ®Google Scholar
• Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2009;53(4):1314–9.10.1128/AAC.01182-08
   PubMed Web of Science ®Google Scholar
• Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009;180(4):371–6.10.1164/rccm.200904-0611OC
   PubMed Web of Science ®Google Scholar
• Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58(1):495–502.10.1128/AAC.01903-13
   PubMed Web of Science ®Google Scholar
• New TB drugs – AZD5847. 2016. [cited 2017 Mar 8]. Available from: http://www.newtbdrugs.org/pipeline/compound/azd5847
   Google Scholar
• Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis. Science. 2005;307(5707):223–7.10.1126/science.1106753
   PubMed Web of Science ®Google Scholar
• Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3(6):323–4.10.1038/nchembio884
   PubMed Web of Science ®Google Scholar
• Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008;283(37):25273–25280.10.1074/jbc.M803899200
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls. Tuberculosis. 2014;94(4):357–62.10.1016/j.tube.2014.04.001
   PubMed Web of Science ®Google Scholar
• Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis. 2015;6(4):170–84.10.1177/2040622315582325
   PubMed Web of Science ®Google Scholar
• Leibert E, Danckers M, Rom WN. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag. 2014;10:597–602.10.2147/TCRM
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–405.10.1056/NEJMoa0808427
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–32.10.1056/NEJMoa1313865
   PubMed Web of Science ®Google Scholar
• Guglielmetti L, Le Du D, Jachym M, Henry B, Martin D, Caumes E, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60(2):188–94.10.1093/cid/ciu786
   PubMed Web of Science ®Google Scholar
• Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014;48(1):107–15.10.1177/1060028013504087
   PubMed Web of Science ®Google Scholar
• Winter H, Egizi E, Murray S, Erondu N, Ginsberg A, Rouse DJ, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015;59(2):1219–24.10.1128/AAC.04171-14
   PubMed Web of Science ®Google Scholar
• Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PloS One. 2015;10(3):e0120763.10.1371/journal.pone.0120763
   PubMed Web of Science ®Google Scholar
• Xu H-B, Jiang R-H, Xiao H-P. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(11):1104–10.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191(8):943–53.10.1164/rccm.201410-1801OC
   PubMed Web of Science ®Google Scholar
• Pule CM, Sampson SL, Warren RM, Black PA, van Helden PD, Victor TC, et al. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016;71(1):17–26.10.1093/jac/dkv316
   PubMed Web of Science ®Google Scholar
• Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013;19(9):1157–60.10.1038/nm.3262
   PubMed Web of Science ®Google Scholar
• Rayasam GV, Balganesh TS. Exploring the potential of adjunct therapy in tuberculosis. Trends Pharmacol Sci. 2015;36(8):506–13.10.1016/j.tips.2015.05.005
   PubMed Web of Science ®Google Scholar
• Ndlovu H, Marakalala MJ. Granulomas and inflammation: host-directed therapies for tuberculosis. Front Immunol. 2016;7:434.
   PubMed Web of Science ®Google Scholar
• Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511(7507):99–103.10.1038/nature13489
   PubMed Web of Science ®Google Scholar
• Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona P-J. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis. 2013;208(2):199–202.10.1093/infdis/jit152
   PubMed Web of Science ®Google Scholar
• Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother. 2016;71(6):1570–7.10.1093/jac/dkw014
   PubMed Web of Science ®Google Scholar
• Restrepo BI. Metformin: candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Tuberculosis. 2016;101:S69–S72.10.1016/j.tube.2016.09.008
   Web of Science ®Google Scholar
• Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, et al. Identification of host-targeted small molecules that restrict intracellular mycobacterium tuberculosis growth. PLoS Pathog. 2014;10(2):e1003946.10.1371/journal.ppat.1003946
   PubMed Web of Science ®Google Scholar
• Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med. 2015;7(2):127–39.10.15252/emmm.201404137
   PubMed Web of Science ®Google Scholar
• Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother. 2015;59(1):673–6.10.1128/AAC.04019-14
   PubMed Web of Science ®Google Scholar
• Migliori GB, Pontali E, Sotgiu G, Centis R, D’Ambrosio L, Tiberi S, et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci. 2017;18(2):341.10.3390/ijms18020341
   Web of Science ®Google Scholar
• Working group on new TB drugs. 2016. [cited 2017 Mar 8]. Available from: http://www.newtbdrugs.org
   Google Scholar
• Clinical trial progress report resist-TB. 2017. [cited 2017 Mar 8]. Available from: http://www.resisttb.org/?page_id=1602
   Google Scholar
• Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC. Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study. J Pharm Policy Pract. 2014;7(1):14.10.1186/2052-3211-7-14
   PubMedGoogle Scholar